Human CD19Targeted T Cells not checked
Hrain Biotechnology Co., Ltd. · CD19 CAR-T
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of predetermined level CAR-positive T cells will be infused.”In the company’s words, NCT05436223 on ClinicalTrials.gov
- Tested for
- CD19-positive (2 trials), B-cell Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukemia
- Main trialPhase 2
- “A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.”In the company’s words, NCT05436223 on ClinicalTrials.gov
- Other names
- CD19 CAR-T
Other drugs for B-cell Non-Hodgkin's Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Unknown | 9 Aug 2024 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | |
| Phase 1Unknown | Oct 2021 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | |
| Phase 1Unknown | Jan 2022 | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026